| 000 | 02648cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031822.0 | ||
| 008 | 171009s2017 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.19.04.M.Sc.2017.Mo.N | ||
| 100 | 0 | _aMostafa Maher Elgammal | |
| 245 | 1 | 0 |
_aNeoadjuvant versus adjuvant chemotherapy in advanced ovarian carcinoma / _cMostafa Maher Elgammal ; Supervised Hanan Ramadan Nassar , Ihab Samy Fayek , Alfred Elias Namour |
| 246 | 1 | 5 | _aمقارنة بين العلاج الكيمائى السابق أو اللاحق للجراحة فى سرطان المبيض المتقدم |
| 260 |
_aCairo : _bMostafa Maher Elgammal , _c2017 |
||
| 300 |
_a102 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology(Medical) | ||
| 520 | _aOvarian cancer is the fifth most common type of cancer and the most common cause of death among women with gynecological malignancies. The aim of this retrospective study was to assess whether there is an advantage of treating women with advanced ovarian cancer with chemotherapy before cytoreductive surgery (neoadjuvant chemotherapy (NACT)) compared with conventional treatment where chemotherapy follows maximal cytoreductive surgery. Methods and materials: Include patients with advanced epithelial ovarian cancer (stage III and IV) who underwent surgery from 2009-2015 with optimal cyto-reductive surgery (R0). Results: The study included 60 patients the mean age for all the patients was 53.7 years . A total of 60 patients diagnosed and treated in NCI and Agouza Police hospital in the specified period (2009-2015), with locally advanced epithelial ovarian carcinoma. They are divided into 2 groups according to pattern of treatment where 30 patients seemed resectable and primary cytoreductive surgery was carried out, and 30 patients seemed unresectable and neoadjuvant chemotherapy was given to them. On assessment of the survival we compared the whole number of both groups. The median overall survival time was 45.77 months in the conventional group and 49.06 month in the NACT group | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAdvanced ovarian carcinoma | |
| 653 | 4 | _aCompletecyto | |
| 653 | 4 | _aNeoadjuvant chemotherapy | |
| 700 | 0 |
_aAlfred Elias Namour , _eSupervisor |
|
| 700 | 0 |
_aHanan Ramadan Nassar , _eSupervisor |
|
| 700 | 0 |
_aIhab Samy Fayek , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c62830 _d62830 |
||